Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness

OBJECTIVE: To evaluate clinical and laboratory effects of delaying ocrelizumab infusions during the COVID-19 pandemics in people with multiple sclerosis (pwMS). METHODS: We have retrospectively searched our electronic database and identified 33 pwMS who had a delay in treatment due to COVID-19 pande...

Descripción completa

Detalles Bibliográficos
Autores principales: Barun, Barbara, Gabelić, Tereza, Adamec, Ivan, Babić, Antonija, Lalić, Hrvoje, Batinić, Drago, Krbot Skorić, Magdalena, Habek, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021462/
https://www.ncbi.nlm.nih.gov/pubmed/33370649
http://dx.doi.org/10.1016/j.msard.2020.102704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021462/
https://www.ncbi.nlm.nih.gov/pubmed/33370649
http://dx.doi.org/10.1016/j.msard.2020.102704

Ejemplares similares